Baxter in $200 million agreement with Corning Clinical Laboratories (CCL)
This article was originally published in Clinica
A five-year, sole-source supply agreement with Corning Clinical Laboratories is expected to result in $200 revenues for Baxter Healthcare. Products to be provided are laboratory and diagnostic supplies, including Dade International's MicroScan system and haemostasis products. Baxter retained exclusive distribution rights in the US for Dade products when it sold its diagnostic manufacturing division to Bain Capital last year (see Clinica No 624, p 1).
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.